Prognostic-disability Biomarkers in Multiple Sclerosis: Review of the Literature from the Last Five Years/Multipl Skleroz Olgularinda Prognoz-Ozurluluk Biyoisaretcileri: Son Bes Yila Ait Literaturun Gozden Gecirilmesi

With the advent of new agents in the treatment of multiple sclerosis, new treatment modalities have emerged (escalation-induction therapy) and the increased efficacy of the drugs has led to increased drug-related risks. The risk/benefit balance has become more carefully assessed. The increased need for reliable markers to predict prognosis-disability has also led to an increase in research conducted in this area. In this short review, studies published between 2012-2017, especially those related to prognosis and disability, were compiled. Keywords: Multiple sclerosis, disability, prognosis, biomarker Multipl skleroz hastaligi tedavisine yeni ajanlarin girmesi ile yeni tedavi modelleri olusmus (basamakli tedavi-indüksiyon tedavisi) ve ilaçlarin artan etkinligi beraberinde ilaç ile iliskili artan riskleri de tasimistir. Risk/yarar dengesi daha dikkatle degerlendirilir hale gelmistir. Prognozu-özürlülügü tahmin ettiren güvenilir isaretçilere artan gereksinim ile bu alanda yapilan arastirmalar da artma göstermistir. Bu kisa gözden geçirme çalismasinda 2012-2017 yillari arasinda yapilmis yayinlarda özellikle prognoz ve özürlülük ile iliskili olanlar derlenmistir. Anahtar Kelimeler: Multipl skleroz, özürlülük, prognoz, biyoisaretçi